BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has reached a financial milestone that many smaller biotechnology companies never reach: an approved treatment is generating recurring revenue and supporting the development of additional drugs. The question now is whether that commercial foundation can withstand a more competitive hereditary angioedema market.
In September, Pharvaris, a late-stage biopharmaceutical company developing treatments for hereditary angioedema (HAE), reported positive Phase 3 results for its investigational oral preventive therapy, deucrictibant XR. The treatment reduced HAE attack rates by 83% compared with placebo, although the trial did not directly compare its effectiveness with BioCryst’s Orladeyo. The results nevertheless introduce a potential future competitor in the oral HAE prevention market, raising questions about whether BioCryst Pharmaceuticals, Inc. can sustain Orladeyo’s revenue growth as additional treatment options emerge.
BioCryst ranks ninth among the 10 best growth stocks under $50 to buy now, offering a biotechnology angle in a ranking that spans several industries. But eight companies attracted greater hedge fund interest. Are investors showing more conviction in established revenue-generating businesses, emerging technology platforms, or another biotechnology opportunity?
Headline Revenue Conceals a Different Product Trend
BioCryst Pharmaceuticals, Inc. reported second-quarter 2026 revenue of $218.3 million, up 34% YoY. However, $55.7 million came from licensing revenue associated with navenibart, accounting for roughly one-quarter of the total. Orladeyo generated $158.2 million, increasing only 1% on a reported basis, or approximately 10% on management’s comparable basis after adjusting for changes in European operations.
Operating profit reached $98.5 million, while non-GAAP operating profit was $113.2 million. Those figures show real financial progress, but licensing recognition should not be treated as equivalent to recurring Orladeyo sales. The company expects 2026 Orladeyo revenue of $625 million to $645 million within total revenue guidance of $690 million to $715 million.
One unconventional investor has read the competitive threat differently: an AI-directed portfolio recently bought BioCryst after Pharvaris’ clinical results. That experiment does not establish investment merit, but its reasoning highlights the debate about how quickly new competition might erode Orladeyo’s position.
Pediatric Growth Buys Time for the Next Product
BioCryst Pharmaceuticals, Inc. began shipping its Orladeyo oral-pellet formulation for pediatric patients in August, broadening the approved population it can serve. The company also completed enrollment in the pivotal ALPHA-ORBIT study of navenibart, with top-line results expected in the third quarter of 2027.
The pediatric opportunity may help Orladeyo maintain sales while navenibart advances, but the long-term stakes are significant. RBC Capital downgraded BioCryst to Sector Perform from Outperform on September 10 and reduced its target to $11 from $13. Citing Pharvaris’ results, RBC contemplated an eventual Orladeyo revenue tail of $400 million to $450 million. At the $425 million midpoint, that is about one-third below the midpoint of management’s 2026 sales guidance, although RBC did not present it as an imminent outcome.
Wedbush retained Outperform with a $20 target (from $21), emphasizing Orladeyo’s performance despite new preventive treatments. Our earlier examination asks whether the pediatric approval could prove more consequential than the announcement suggests, particularly if the company can build a longer-lasting commercial franchise.
A Low Earnings Multiple Still Requires Durable Revenue
Seeking Alpha’s October 13 figures put BioCryst Pharmaceuticals, Inc. at 10.83 times forward non-GAAP earnings against a healthcare sector median of 19.02. The projected P/E falls from 12.16 in 2027 to 10.60 in 2028 and 7.46 in 2029, alongside estimated EPS growth of 14.77% in 2028 and 42.05% in 2029. Those forecasts presume that the company can sustain profitability beyond one-time revenue recognition.
Meanwhile, the balance sheet adds a constraint: approximately $352.6 million in cash and investments, against $395.4 million in secured term loans and $426.8 million in royalty financing obligations. Hedge fund ownership eased from 47 to 46 funds in Q2, while short interest declined to 27.49 million shares as of September 30, but remained elevated.
For BioCryst Pharmaceuticals, Inc., the deciding variable is recurring Orladeyo demand during the wait for navenibart. BioCryst’s low forward earnings multiple suggests investors may already be pricing in some competitive pressure on Orladeyo. Whether the stock is genuinely undervalued will depend on how well recurring sales hold up as new treatments enter the market.
READ NEXT: Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable? and Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet
